Skip to content

Clinical study of mesalazine with probiotics to improve senile UC

Clinical study of mesalazine with probiotics to improve senile UC

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098522
Enrollment
Unknown
Registered
2025-03-10
Start date
2025-03-25
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild active ulcerative colitis

Interventions

Experimental group:Lactobacillus johnsonii+Mesalazine

Sponsors

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.>= 60 years old. 2. Clear diagnosis of mild active ulcerative colitis (i.e. diagnosis based on symptoms, laboratory tests, endoscopic findings; assessment of ulcerative colitis activity based on modified Mayo score). 3. Not adjusting the dosage of previous treatment drugs (including 5-aminosalicylic acid, immunosuppressants, biologics, etc.) within 2 weeks. 4. Not taking probiotics and related products within 2 weeks. 5. Voluntarily participate in this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Used antibiotics within 2 weeks prior to treatment. 2. Current intestinal infection. 3. Use NSAIDs continuously for the first 5 days. 4. History of gastrointestinal surgery. 5. Serious systemic diseases, important organ diseases such as heart, lung, brain, liver and kidney dysfunction, malignant tumors, and other related diseases. 6. Individuals who are allergic to any component of probiotics observed. 7. Individuals who have participated in other intervention studies within the past 3 months prior to treatment or are unable to express their main complaints correctly or cooperate. 8. Pregnant or lactating women. 9. Vulnerable groups other than the elderly, including those with mental illness, cognitive impairment, critically ill patients, illiterate individuals, etc.

Design outcomes

Primary

MeasureTime frame
Sigmoidoscopy;Concentration of blood metabolites of Lactobacillus johnsonii;

Secondary

MeasureTime frame
Blood cell analysis and other blood indicators;Fecal analysis and other fecal indicators;Microbial abundance detection of fecal samples;

Countries

China

Contacts

Public ContactShujie Chen

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

4094108@qq.com+86 571 86006144

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026